| Background | Crizanlizumab is a humanized monoclonal antibody directed against P-selectin that showed effectiveness in preventing VOC induced pain crises. Median rate of pain crises was 1.63 in crizanlizumab treated group versus 2.998 in placebo group. Furthermore, the median time to crisis was 4.07 months with crizanlizumab compared to 1.38 in the placebo group. The benefits of treatment held true within subgroups including those with a high number of VOC prior to treatment and those with more severe genotype. The drug is FDA approved to reduce the frequency of VOC in adults and pediatric patients with SCD aged 16 years and older. |
|---|
